For over a century, scientists have been fascinated by bacteriophages, the tiny viruses that naturally hunt and kill bacteria. University of Otago researchers are turning to these microscopic ...

Shares of Cardiff Oncology Inc. (NASDAQ:CRDF) were trading at $1.92, down 1.03, or 35%, after an update with the Polo-like kinase 1 (PLK1) inhibitor onvansertib, undergoing tests in the phase II trial ...

More than two years after its approval, only about 60 patients across the U.S., Middle East, and Europe have been treated with the gene-editing therapy. Specialists at four sickle centers told STAT ...

A small change to a powerful molecular tool — using the CRISPR-Cas13 enzyme, which can detect RNA from viruses and cells — ...

Microbiologist John van der Oost of Wageningen University & Research (WUR) has received an ERC Proof of Concept grant to further develop a promising CRISPR-based approach to cancer treatment. With ...

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...

At 3 months old, Victoria Gray wouldn’t stop crying. Blood tests brought devastating news: she had sickle cell disease, a genetic blood disorder that blocks blood flow and oxygen delivery to the body.

Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. Last February ...

Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most known CRISPR systems target invading pathogens' DNA and chop it up to ...